Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The Biochemical Journal|March 21, 2002
Involvement of protein kinase D in Fc gamma-receptor activation of the NADPH oxidase in neutrophilsJan K Davidson-Moncada, Guillermo Lopez-Lluch, Anthony W Segal, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 24, 2009
Protein kinase C as an effector of lipid-derived second messengersMarie-Hélène Paclet, Jan K Davidson-Moncada, Guillermo López-Lluch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
<i>In Vivo</i> Tracking of Adoptively Transferred Natural Killer Cells in Rhesus Macaques Using <sup>89</sup>Zirconium-Oxine Cell Labeling and PET ImagingNoriko Sato, Kate Stringaris, Jan K Davidson-Moncada, et al.
Molecular Therapy Oncolytics|January 26, 2023
Expanded NK cells used for adoptive cell therapy maintain diverse clonality and contain long-lived memory-like NK cell populationsDavid S J Allan, Chuanfeng Wu, Ryland D Mortlock, et al.
Science Immunology|November 4, 2018
Clonal expansion and compartmentalized maintenance of rhesus macaque NK cell subsetsChuanfeng Wu, Diego A Espinoza, Samson J Koelle, et al.
Blood|February 18, 2017
Adaptive NK cells can persist in patients with <i>GATA2</i> mutation depleted of stem and progenitor cellsHeinrich Schlums, Moonjung Jung, Hongya Han, et al.
Blood Advances|December 22, 2020
Intrabone transplantation of CD34+ cells with optimized delivery does not enhance engraftment in a rhesus macaque modelKate Stringaris, Robert F Hoyt, Jan K Davidson-Moncada, et al.
Blood Advances|October 15, 2020
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AMLJayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, et al.
Science Translational Medicine|June 5, 2020
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemiaJayakumar Vadakekolathu, Mark D Minden, Tressa Hood, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Pageof 2